ISDA

Entry Detail

PDB ID:

4CD0

Keywords:

Title:

Structure of L1196M Mutant Human Anaplastic Lymphoma Kinase in Complex with 2-(5-(6-amino-5-((R)-1-(5-fluoro-2-(2H-1,2,3-triazol-2- yl)phenyl)ethoxy)pyridin-3-yl)-4-methylthiazol-2-yl)propane-1,2-diol

Biological Source:

Source Organism:

HOMO SAPIENS

Host Organism:

SPODOPTERA FRUGIPERDA

PDB Version:

Deposition Date:

2013-10-29

Release Date:

2014-01-29

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.23 Å

R-Value Free:

0.25

R-Value Work:

0.19

R-Value Observed:

0.19

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:ALK TYROSINE KINASE RECEPTOR
Mutations:YES
Chain IDs:A
Chain Length:342
Number of Molecules:1
Biological Source:HOMO SAPIENS

UniProt ID:Q9UM73 Pfam ID:PF07714 EC:2.7.10.1

Ligand Molecules

AWJ

Primary Citation

The Design of Potent and Selective Inhibitors to Overcome Clinical Alk Mutations Resistant to Crizotinib.

Huang, Q, Johnson, T.W, Bailey, S, Brooun, A, Bunker, K.D, Burke, B.J, Collins, M.R, Cook, A, Cui, J.J, Dack, K.N, Deal, J.G, Deng, Y, Dinh, D.M, Engstrom, L.D, He, M, Hoffman, J, Hoffman, R.L, Shen, H, Johnson, P, Kania, R.S, Lam, H, Lam, J.L, Le, P, Li, Q, Lingardo, L, Liu, W, West Lu, M, Mctigue, M.A, Palmer, C.L, Richardson, P.F, Sach, N.W, Smeal, T, Smith, G.L, Stewart, A.E, Timofeevski, S.L, Tsaparikos, K, Wang, H, Zhu, H, Zhu, J, Zou, H.Y, Edwards, M.Show

J.Med.Chem. 57 1170 ? (2014)

PMID: 24432909 DOI: 10.1021/JM401805H

Abstact

Crizotinib (1), an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S. Food and Drug Administration in 2011, is efficacious in ALK and ROS positive patients. Under pressure of crizotinib treatment, point mutations arise in the kinase domain of ALK, resulting in resistance and progressive disease. The successful application of both structure-based and lipophilic-efficiency-focused drug design resulted in aminopyridine 8e, which was potent across a broad panel of engineered ALK mutant cell lines and showed suitable preclinical pharmacokinetics and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M).

Legend

Protein

Chemical

Disease

Primary Citation of related structures